Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support Add lines 7 through 10. | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 8,931,139 | 7,731,584 | 9,951,001 | 8,477,875 | 9,775,055 | 44,866,654 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | 70,399,472 | 72,435,660 | 73,138,765 | 76,312,383 | 83,008,682 | 375,294,962 |
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | 0 | |||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | 0 | |||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 6 | Total. Add lines 1 through 5. | 79,330,611 | 80,167,244 | 83,089,766 | 84,790,258 | 92,783,737 | 420,161,616 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | 12,940,190 | 10,563,934 | 13,094,217 | 11,456,835 | 12,876,427 | 60,931,603 |
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | |||||
| c | Add lines 7a and 7b.. | 12,940,190 | 10,563,934 | 13,094,217 | 11,456,835 | 12,876,427 | 60,931,603 |
| 8 | Public support (Subtract line 7c from line 6.) | 359,230,013 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 79,330,611 | 80,167,244 | 83,089,766 | 84,790,258 | 92,783,737 | 420,161,616 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 944,781 | 2,794,882 | 4,333,604 | 5,333,603 | 5,821,197 | 19,228,067 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | 0 | |||||
| c | Add lines 10a and 10b. | 944,781 | 2,794,882 | 4,333,604 | 5,333,603 | 5,821,197 | 19,228,067 |
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | 1,661,960 | 2,108,381 | 3,049,601 | 3,403,799 | 3,584,676 | 13,808,417 |
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | 0 | |||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 81,937,352 | 85,070,507 | 90,472,971 | 93,527,660 | 102,189,610 | 453,198,100 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e | Discount claimed for blockage or other factors (explain in detail in Part VI): | |||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| 7 | Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions) | |||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2014 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2014 |
(iii) Distributable Amount for 2014 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2014 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2014 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2014: | ||||
| a From 2009.......X | ||||
| b From 2010.......X | ||||
| c From 2011.......X | ||||
| d From 2012.......X | ||||
| e From 2013....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2014 distributable amount | ||||
|
i
Carryover from 2009 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2014 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2014 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2014, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2014. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2015. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a From 2010.......X | ||||
| b From 2011.......X | ||||
| c From 2012.......X | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4D | CANCER POLICY AND CLINICAL AFFAIRS: ASCO'S CANCER POLICY AND CLINICAL AFFAIRS DEPARTMENT ADDRESSES POLICY ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, CANCER RESEARCH, CARE AND PREVENTION. THE DEPARTMENT WORKS WITH VOLUNTEER COMMITTEES AND ASCO LEADERS TO SHAPE POLICY, LAW AND REGULATION ON ISSUES OF IMPORTANCE IN ONCOLOGY. THE DEPARTMENT'S PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING PATIENT-ORIENTED RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ACTIVITIES INCLUDE HOTLINES, TOOLS, EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. CANCER POLICY AND CLINICAL AFFAIRS STAFF INTERACT AND COLLABORATE ON A REGULAR BASIS WITH ASCO STATE AND REGIONAL AFFILIATES, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE. THE STATE/REGIONAL AFFILIATE PROGRAM: THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO BETTER ADDRESS ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. FEDERAL POLICIES IMPACTING CANCER CARE AND RESEARCH: ASCO REVIEWS AND FREQUENTLY COMMENTS ON POLICIES ISSUED BY FEDERAL AGENCIES, INCLUDING THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS), FOOD AND DRUG ADMINISTRATION (FDA), AND NATIONAL INSTITUTES OF HEALTH (NIH). STAFF AND VOLUNTEERS ALSO ACTIVELY PARTICIPATE IN AMERICAN MEDICAL ASSOCIATION (AMA) PROCESSES FOR DEVELOPMENT OF NEW CPT CODES AND VALUATION OF CODES THROUGH THE AMA/SPECIALTY SOCIETY RELATIVE VALUE SCALE UPDATE COMMITTEE (RUC). MEMBER RELATIONS AND INFORMATION: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 34,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CUTTING EDGE RESEARCH, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE. COMMUNICATIONS AND PATIENT INFORMATION: ASCO PROVIDES THE PUBLIC, INCLUDING PATIENTS, THE MEDIA, LEGISLATORS, PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS, WITH ACCURATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILY MEMBERS AND FRIENDS, THE MEDIA AND HEALTH CARE PROFESSIONALS, THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER. IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT,CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR), BOOKLETS ON TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. ADDITIONAL RESOURCES AVAILABLE ON CANCER.NET. ASCO ALSO PROVIDES THE FOLLOWING INFORMATIONAL SERVICES TO THE PUBLIC: FIND AN ONCOLOGIST DATABASE: A FREE SEARCHABLE DATABASE OF ASCO MEMBERS BY SPECIALTY OR LOCATION FOR THOSE IN NEED OF A SPECIALIST. CANCER ADVANCES: SUMMARIES OF RESEARCH ADVANCES IN CLINICAL ONCOLOGY FROM THE JOURNAL OF CLINICAL ONCOLOGY, ASCO'S ANNUAL MEETINGS, AND ASCO SYMPOSIA. WHAT TO KNOW: ASCO'S GUIDELINES: PATIENT-FRIENDLY GUIDES BASED ON ASCO'S CLINICAL PRACTICE GUIDELINES FOR PHYSICIANS. RESEARCH AND MEETINGS: INFORMATION ON ASCO'S ANNUAL MEETINGS AND SYMPOSIA, VIRTUAL LECTURES, AND ASCO'S EXPERT PERSPECTIVE ON CANCER NEWS. MULTIMEDIA: MEDICAL ILLUSTRATIONS, MOBILE APP, VIDEOS, AND PODCASTS ON TOPICS SUCH AS: CANCER RESEARCH, TREATMENT, AND COPING. EXPERT INFORMATION FROM ASCO: ASCO EXPERTS ANSWER QUESTIONS ABOUT CURRENT TOPICS IN CANCER CARE, TREATMENT, AND RESEARCH. CANCER.NET FEATURE ARTICLES: WEEKLY ARTICLES DESIGNED TO PROVIDE IN-DEPTH INFORMATION ON TOPICS OF INTEREST, AS WELL AS PRACTICAL INFORMATION ON CANCER CARE AND TREATMENT. ASCO CANCER TREATMENT SUMMARY FORMS: PRINTABLE FORMS PATIENTS AND THEIR DOCTORS CAN COMPLETE TO HELP KEEP TRACK OF TREATMENT PLANS AND FOLLOW-UP CARE PLANS. CANCER.NET EN ESPANOL: TRANSLATED CONTENT ON THE TREATMENT OF COMMON CANCER TYPES, MANAGING SIDE EFFECTS, AN INTRODUCTION TO CLINICAL TRIALS, SURVIVORSHIP, AND ASCO'S GUIDELINES. SEVERAL PRINTED PIECES ARE ALSO AVAILABLE IN SPANISH. |
| FORM 990, PART VI, SECTION A, LINE 1 | AS OF DECEMBER 31, 2014, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. |
| FORM 990, PART VI, SECTION A, LINE 6 | ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCOS PROFITS OR EXCESS DUES OR A SHARE OF ASCOS NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. 2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 65, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. 3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. |
| FORM 990, PART VI, SECTION A, LINE 7A | VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. |
| FORM 990, PART VI, SECTION A, LINE 7B | ASCOS CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. |
| FORM 990, PART VI, SECTION B, LINE 11 | AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE VICE PRESIDENT AND GENERAL COUNSEL PRIOR TO FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C | CCF MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CCF STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CCF'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED WHEN ANY MATERIAL CHANGES OCCUR. IN ADDITION, CCF OFFICERS, DIRECTORS, AND KEY EMPLOYEES ARE REQUIRED TO DISCLOSE ANNUALLY BUSINESS RELATIONSHIPS OR ANY TRANSACTIONS THEY OR THEIR RELATED ENTITIES OR FAMILY MEMBERS HAVE WITH CCF OR WITH OTHER OFFICERS, DIRECTORS OR KEY EMPLOYEES. CCF'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CCF IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CCF DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF); THE PRESIDENT OF ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM AND D/B/A CANCERLINQ); THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF DIRECTORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. VICE PRESIDENT/GENERAL COUNSEL: THE COMPENSATION OF THE VICE PRESIDENT/GENERAL COUNSEL (VP/GC) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE VP/GC WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE VP/GC AND ASCO ADDRESSES COMPENSATION OF THE VP/GC. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP/GC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. CHIEF FINANCIAL OFFICER (CFO). THE COMPENSATION OF THE CHIEF FINANCIAL OFFICER (CFO) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. EXECUTIVE DIRECTOR OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF): THE EXECUTIVE DIRECTOR OF CCF IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY: THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. |
| FORM 990, PART VI, SECTION C, LINE 19 | ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. |
| FORM 990, PART XI, LINE 9 | LOSS ON INTEREST RATE SWAP -5,484,047 |
| FORM 990, PART III, LINE 4A | CONTINUATION OF PROGRAM SERVICE ACCOMPLISHMENT: THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND ASSIST THEM IN PROVIDING WORLD CLASS CANCER CARE AND IN CONDUCTING CUTTING EDGE RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY,ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2014 ACTIVITIES INCLUDE: OVER 34,000 PEOPLE ATTENDED THE 2014 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES,CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. MORE THAN HALF OF ATTENDEES AT THE 2014 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2014 ANNUAL MEETING FEATURED OVER 220 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 4,500 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 3,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORED OR CO-SPONSORED OVER 50 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN AND AROUND THE WORLD. THESE MEETINGS INCLUDED: - BEST OF ASCO CENTRAL - BEST OF ASCO EASTERN - BEST OF ASCO WESTERN - PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM - ASCO'S QUALITY CARE SYMPOSIUM - GI CANCERS SYMPOSIUM - GU CANCERS SYMPOSIUM - BREAST CANCER SYMPOSIUM - ASCO/AACR METHODS WORKSHOP INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - BEST OF ASCO INTERNATIONAL (24) - JOINT SYMPOSIA (16) - ADVANCED CANCER COURSES (8) - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES (4) ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS BONUS COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. |
| FORM 990, PART III, LINE 4B | CONTINUATION OF PROGRAM SERVICE ACCOMPLISHMENT: THE JOURNALS INCLUDE ORIGINAL REPORTS, SELECTED EDITORIALS, COMMENTARIES, REVIEWS, AND OTHER WORK THAT RELATES TO THE CARE OF PATIENTS WITH CANCER. JCO IS TRANSLATED INTO A NUMBER OF LANGUAGES IN INTERNATIONAL EDITIONS, THERBY INCREASING ITS USE INTERNATIONALLY. IN 2014 JOURNAL OF CLINICAL ONCOLOGY HAD OVER 26,000 ANNUAL SUBSCRIBERS. ADDITIONALLY, AS REPORTED BY THOMSON REUTERS IN ITS 2013 JOURNAL CITATION REPORT, JCO'S IMPACT FACTOR OF 17.960 RANKED IT #53 OUT OF 8,336 JOURNALS MEASURED AND #5 IN THE ONCOLOGY CATEGORY (196 JOURNALS MEASURED). JCO RECEIVED 120,262 TOTAL CITATIONS IN 2011, WHICH RANKED IT #23 OVERALL AND #2 IN THE ONCOLOGY CATEGORY. JCO'S EIGENFACTOR SCORE OF 0.39463 (A MEASURE OF WHAT TYPES OF CITATIONS WERE GENERATED) RANKED IT #16 OVERALL AND #1 IN THE ONCOLOGY CATEGORY. THE IMPACT FACTOR, TOTAL CITATIONS, AND EIGENFACTOR SCORES ARE ALL REFLECTIONS OF THE VALUE RESEARCHERS FIND IN JCO CONTENT. IN 2013, JOURNAL OF ONCOLOGY PRACTICE (JOP) WAS ACCEPTED FOR INDEXING IN MEDLINE, THE PREMIER BIBLIOGRAPHIC DATABASE OF THE U.S. NATIONAL LIBRARY OF MEDICINE (NLM). THE INCLUSION OF JOP IN MEDLINE GIVES AN INDICATION OF ITS GROWING PROMINENCE AND REPUTATION IN ONCOLOGY AND IS A REFLECTION OF THE VERY HIGH QUALITY OF ITS PUBLISHED ARTICLES. |
| FORM 990, PART III, LINE 4C | CONTINUATION OF PROGRAM SERVICE ACCOMPLISHMENT: PROGRAMS INCLUDE: - CANCERLINQ, AN INITIATIVE TO DEVELOP A RAPID LEARNING SYSTEM IN ONCOLOGY. THIS EFFORT IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, LEARN, AND INTERACT WITH THEIR PATIENTS. FOLLOWING THE PRESENTATION OF A SUCCESSFUL PROOF-OF-CONCEPT PROTOTYPE IN 2013, ASCO FORMALLY INITIATED DEVELOPMENT OF THE FULL CANCERLINQ SYSTEM. - QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. THE PROGRAM IS UNIQUE IN THE CANCER COMMUNITY AND HAS BEEN ACCEPTED BY THE AMERICAN BOARD OF INTERNAL MEDICINE AS A MECHANISM FOR SATISFYING PRACTICE EVALUATION AND IMPROVEMENT REQUIREMENTS FOR MAINTENANCE OF CERTIFICATION. ASCO SUPPORTS A NUMBER OF COLLABORATIVE GROUPS THAT USE QOPI WITHIN THEIR INITIATIVES TO DRIVE THEIR QUALITY IMPROVEMENT EFFORTS. OVER 700 PRACTICES NATIONWIDE, INCLUDING PRACTICES IN HAWAII, ALASKA, GUAM, AND PUERTO RICO, ARE ENROLLED IN THE PROGRAM. - QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE SUCCESS OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE. THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO: - PROMOTE HIGH QUALITY CANCER CARE AS DEFINED BY THE CLINICIAN EXPERTS. - PROVIDE A TRUSTED SOLUTION TO SATISFY EXTERNAL DEMAND FOR QUALITY ACTIVITIES. - REDUCE REDUNDANT PROGRAMS OR ADMINISTRATIVE BURDENS RELATED TO THE DEMONSTRATION OF QUALITY. THE QOPI CERTIFICATION PROGRAM IS CARRIED OUT BY A SPECIAL-PURPOSE LIMITED LIABILITY CORPORATION (LLC), ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM). THE SOLE MEMBER OF THIS LLC IS ASCO AND THE PRESIDENT IS ASCO'S CHIEF EXECUTIVE OFFICER. - NEW GUIDELINES AND ONGOING UPDATES. ASCO HAS PUBLISHED OVER 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. |
| FORM 990 PART IX LINE 11G | DESCRIPTION:COMMISSIONS TOTAL FEES:2930500 |
| FORM 990 PART IX LINE 11G | DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1440146 |
| FORM 990 PART IX LINE 11G | DESCRIPTION:OTHER PROFESSIONAL SERVICES TOTAL FEES:8433122 |
| Software ID: | |
| Software Version: |